Financial Performance Overview

Astec LifeSciences Limited announced its unaudited financial results for the quarter ended 30th June, 2026 (Q1 FY27). The consolidated financial highlights are as follows:

Consolidated Results (in ₹ crore)

| Metric | Q1 FY27 | Q1 FY26 | % Change |

| Total Income | 84.3 | 91.6 | -8.0% |

| EBITDA | 0.1 | -10.5 | NM (Not Measurable) |

| Loss After Tax | -18.7 | -33.0 | NM |

  • Total income decreased by 8.0% year-over-year (YoY) from ₹91.6 crore in Q1 FY26 to ₹84.3 crore in Q1 FY27.
  • EBITDA improved significantly to ₹0.1 crore in Q1 FY27 from a loss of ₹10.5 crore in Q1 FY26, indicating breakeven.
  • Loss after tax narrowed to ₹18.7 crore in Q1 FY27 from ₹33.0 crore in Q1 FY26, a reduction in loss.

Segment-wise Performance Breakdown

Revenue from Operations (in ₹ crore)

| Category | Q1 FY27 | Q1 FY26 | % Change |

| Enterprise Products | 51.8 | 36.5 | 41.6% |

| Contract Manufacturing & New Products (CDMO) | 31.8 | 54.6 | -41.8% |

  • Enterprise products revenue increased by 41.6% YoY to ₹51.8 crore in Q1 FY27 from ₹36.5 crore in Q1 FY26, primarily due to higher volumes and improved realizations.
  • Contract Manufacturing & New Products (CDMO) revenue decreased by 41.8% YoY to ₹31.8 crore in Q1 FY27 from ₹54.6 crore in Q1 FY26, attributed to a high base in the corresponding quarter.

Geographical Revenue Breakdown

| Geography | Q1 FY27 | Q1 FY26 | % Change |

| Exports | 33.3 | 45.9 | -27.5% |

| Domestic | 50.3 | 45.2 | 11.3% |

  • Export revenue declined by 27.5% YoY to ₹33.3 crore in Q1 FY27 from ₹45.9 crore in Q1 FY26.
  • Domestic revenue increased by 11.3% YoY to ₹50.3 crore in Q1 FY27 from ₹45.2 crore in Q1 FY26.

Management Commentary

Mr. Vishal Sharma, Chairperson of Astec LifeSciences Limited, provided comments on the performance:

  • The agrochemical sector is still dealing with demand-supply imbalance since 2023, which is expected to even out over the medium term, structurally supporting the industry.
  • The improvement in EBITDA to breakeven despite lower revenues was supported by favourable product mix, improved margins in both Enterprise and Contract Manufacturing segments, and enhanced capacity utilization at its plants.
  • The company is taking steps to build business development and growth capabilities, along with new product introductions, and exploring opportunities to drive operational efficiencies.